ERBB2 and breast cancer: In the current study, looking at the analytic validation, we demonstrated a significant level of accuracy for PID testing by comparing HER2 PID quantitation in cell pellets of six well categorized HER2 breast cancer cell lines to an established reference method (FACS analysis) in the same six cell lines (Fig. 3a., R2 = 0.99).